Peptide encyclopedia
Every compound indexed here carries mechanism, route of administration, half-life, legal status, and the primary sources backing every claim — graded and dated.
- Compounds
- 75
- Source links
- 249
- Therapeutic classes
- 10
- Matching filter
- 8
F·Filter
Reset allCognitive
Nootropic and neuroprotective compounds with hippocampal action.
8 compounds
01
Prescription only
Cerebrolysin
FPF-1070 · Cerebrolysin Concentrate · et al.
Cerebrolysin is the peptide product on this site with the largest randomized-controlled-trial body and also the one for which the most authoritative independent reviewer — the Cochrane Stroke Group — has concluded the trial body does not yet support routine use; the page treats both facts as load-bearing.
Half-life·Pharmacokinetics are not characterized in the conventional s…
Read entry
02
Research use only
Dihexa
PNB-0408 · N-hexanoyl-Tyr-Ile-(6)aminohexanoic amide
Dihexa is the most ambitious cognitive peptide in this corpus and the one with the largest evidence gap — preclinical synaptogenesis and Alzheimer's-model results that landed on covers, paired with zero published human trials.
Half-life·~10 days plasma half-life in rodents on oral administration;…
Read entry
03
Research use only
Fosgonimeton
ATH-1017 · NDX-1017 · et al.
Fosgonimeton is the clinical-development case study in the dihexa pharmacology lineage — a small-molecule HGF/MET modulator engineered for subcutaneous bioavailability that reached a 554-patient Phase 2/3 in mild-to-moderate Alzheimer's disease and missed every prespecified clinical endpoint despite moving p-tau217 in the direction the mechanism predicted.
Half-life·Subcutaneously administered prodrug rapidly converted to the…
Read entry
04
Research use only
GPE
Glycyl-Prolyl-Glutamate · Gly-Pro-Glu · et al.
GPE is unusual in this corpus: the parent peptide has thirty years of preclinical neuroprotection data and no human controlled trials of native GPE for any indication, while its engineered analog became the first FDA-approved drug for Rett syndrome in 2023. The gray-market case rides on the clinical-development success of a related molecule, not on its own.
Half-life·Plasma half-life of native GPE is short — minutes in rodent …
Read entry
05
Research use only
Pituitary Adenylate Cyclase-Activating Polypeptide
pituitary adenylate cyclase-activating polypeptide · PACAP-38 · et al.
PACAP is the second-validated migraine-mechanism neuropeptide after CGRP — the same trigeminal-sensory-nerve release, the same migraine-provocation result when infused into migraineurs, and the same antibody-blockade therapeutic strategy that produced the CGRP class. The Lundbeck HOPE Phase 2 (NEJM 2024) is the first controlled-trial evidence that anti-PACAP blockade reduces monthly migraine days in patients who failed the CGRP class.
Half-life·Plasma half-life of intravenously infused PACAP-38 is short …
Read entry
06
Research use only
Selank
TKPRPGP · Selanc
Selank's evidence base is real but parallel — three decades of Russian clinical use sits alongside a much thinner Western peer-reviewed literature, and both belong on the page.
Half-life·Plasma half-life is brief (minutes), but the rodent and clin…
Read entry
07
Research use only
Semax
MEHFPGP · ACTH(4-7) Pro-Gly-Pro · et al.
Semax sits in the same evidence-depth gap as Selank — three decades of Russian clinical use in stroke and cognitive indications alongside a much thinner Western peer-reviewed literature, and the page covers both honestly.
Half-life·Plasma half-life is brief (minutes); the protective Pro-Gly-…
Read entry
08
Prescription only
Trofinetide
NNZ-2566 · Daybue · et al.
Trofinetide is the engineered descendant of the GPE pharmacology lineage that became, in March 2023, the first FDA-approved drug for any indication in Rett syndrome — and the page treats both halves of that fact as load-bearing: a genuine regulatory milestone for a previously drug-less condition, paired with a modest pivotal effect size and a diarrhea incidence of approximately 80% that defines real-world tolerability.
Half-life·The 2-methyl-proline substitution at the central residue con…
Read entry